Pemetrexed induced acute kidney injury in patients with non-small cell lung cancer: reversible and chronic renal damage

Journal of Nephrology

Volumn 28, Issue 2, 2015, Pages 187-191

  Rombolà, Giuseppe ^a,b   Vaira, Franco ^a   Trezzi, Matteo ^a   Chiappini, Nadia ^a   Falqui, Valeria ^a   Londrino, Francesco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Macchi Foundation Hospital   (Italy)

Author keywords

Acute kidney injury; Bone marrow toxicity; Not small cell lung cancer; Pemetrexed

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; CISPLATIN; CREATININE; CYANOCOBALAMIN; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FILGRASTIM; FOLIC ACID; FUROSEMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PEMETREXED; RECOMBINANT ERYTHROPOIETIN; STEROID; ANTINEOPLASTIC AGENT;

ACUTE KIDNEY FAILURE; AGED; ARTICLE; BONE MARROW SUPPRESSION; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; HYPERTENSION; INCIDENCE; KIDNEY BIOPSY; LUNG EDEMA; MALE; MORBIDITY; NON SMALL CELL LUNG CANCER; RETROSPECTIVE STUDY; ACUTE KIDNEY INJURY; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; CONTRAINDICATIONS; CONVALESCENCE; LENGTH OF STAY; LUNG NEOPLASMS; MIDDLE AGED; TREATMENT WITHDRAWAL;

ACUTE KIDNEY INJURY; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; LENGTH OF STAY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PEMETREXED; RECOVERY OF FUNCTION; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; WITHHOLDING TREATMENT;

EID: 84925939882     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.1007/s40620-014-0117-5     Document Type: Article

References (27)

1. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21(14):2636–2644
2. Santoro A, O’Brien ME, Stahe RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom L, Liu Y, Ripoche V, Blatter J, Visseren-Gru CM, Manegold C (2008) Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaıve patients with malignant pleural mesothelioma: results of the international expanded access program. J Thorac Oncol 3(7):756–763
3. Schuette WH, Gröschel A, Sebastian M, Andreas S, Müller T, Schneller T, Guetz S, Eschbach C, Bohnet S, Leschinger MI, Reck M (2013) A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer. Clin Lung Cancer 14(3):215–223
4. Socinski MA, Stinchcombe TE, Hayes DN (2005) The evolving role of pemetrexed (Alimta) in lung cancer. Semin Oncol 32(2 Suppl 2):16–22 (Review)
5. Ciuleanu T, Brodowicz T, Zielinski C et al (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374(9699):1432–1440
6. Grønberg BH, Bremnes RM, Fløtten O et al (2009) Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 27(19):3217–3224
7. Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22(9):1589–1597
8. http://www.drugs.com/pro/alimta.html. Accessed 26 Dec 2012
9. http://www.uptodate.com. Accessed 27 Feb 2014
10. Levin A, Warnock DG, Mehta RL et al (2007) Improving outcomes from acute kidney injury: report of an initiative. Am J Kidney Dis 50:1–4
11. Jassem J, Ramlau R, Santoro A et al (2008) Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 26(10):1698–1704
12. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed 27 Feb 2014
13. http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021462lbl.pdf. Accessed 27 Feb 2014
14. Paz-Ares LG, De Marinis F, Dediu M et al (2013) PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 31:2895–2902
15. Glezerman IG, Pietanza MC, Miller V, Seshan SV (2011) Kidney tubular toxicity of maintenance pemetrexed therapy. Am J Kidney Dis 58(5):817–820
16. Vootukuru V, Liew YP, Nally JV Jr (2006) Pemetrexed-induced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small cell lung cancer. Med Oncol 23:419–422
17. Michels J, Spano JP, Brocheriou I, Deray G, Khayat D, Izzedine H (2009) Acute tubular necrosis and interstitial nephritis during pemetrexed therapy. Case Rep Oncol 2:53–56
18. Stavroulopoulos A, Nakopoulou L, Xydakis AM, Aresti V, Nikolakopoulou A, Klouvas G (2010) Interstitial nephritis and nephrogenic diabetes insipidus in a patient treated with pemetrexed. Ren Fail 32:1000–1004
19. Porta JM, Vicente de Vera Floristán C, Inglán PB, Jericó JF (2009) Acute renal failure associated with Pemetrexed (Alimta®). Nefrologia 29:610–611
20. Chauvet S, Courbebaisse M, Ronco P, Plaisier E. Pemetrexed-induced acute kidney injury leadind to chronic kidney disease. Clin Nephrol. 2014 (Epub ahead of print)
21. Perazella MA, Markowitz GS (2008) Bisphosphonate nephrotoxicity. Kidney Int 74:1385–1393
22. Bodmer M, Amico P, Mihatsch MJ et al (2007) Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient. Nephrol Dial Transplant 22:2366–2370
23. Barri YM, Munshi NC, Sukumalchantra S et al (2004) Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 65:634–641
24. Markowitz GS, Appel GB, Fine PL et al (2001) Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 12:1164–1172
25. Desikan R, Veksler Y, Raza S et al (2002) Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma. Br J Haematol 119:496–499
26. McKeage MJ (1995) Comparative adverse effect profiles of platinum drugs. Drug Saf. 13:228–244
27. Hannemann J, Baumann K (1990) Nephrotoxicity of cisplatin, carboplatin and transplatin. Arch Toxicol 64:339–400